45 studies found for:    anti-EGFR antibodies
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Condition: Colorectal Cancer
Intervention: Drug: Everolimus (RAD001)
2 Recruiting BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer
Condition: Cancer
Interventions: Drug: Part 1 Cohort 1: Dabrafenib plus Panitumumab;   Drug: Part 1 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 1 Cohort 3A: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 1 Cohort 3B: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 1 Cohort 4: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 2 Cohort 1: Dabrafenib plus Panitumumab;   Drug: Part 2 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 3 Cohort 1: Dabrafenib plus Panitumumab;   Drug: Part 3 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 3 Cohort 3: 5-fluorouracil-based chemotherapy
3 Recruiting Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Conditions: Epidermoid Carcinoma;   Anus
Interventions: Drug: radiochemotherapy;   Drug: Panitumumab
4 Terminated Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab;   Procedure: conventional surgery;   Radiation: radiation therapy
5 Withdrawn Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
Condition: Head and Neck Cancer
Interventions: Biological: panitumumab;   Drug: cisplatin;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: quality-of-life assessment;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
6 Completed
Has Results
Zalutumumab in Patients With Non-curable Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Cancer
Interventions: Drug: Zalutumumab;   Other: Control
7 Recruiting Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET
Condition: Colorectal Cancer
Intervention: Behavioral: pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles
8 Unknown  Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment
Conditions: Colorectal Cancer;   Skin Toxicities
9 Completed Nimotuzumab in Children With Intrinsic Pontine Glioma
Condition: Diffuse Instrinsic Ponitine Glioma
Intervention: Drug: nimotuzumab
10 Recruiting Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Condition: Ras-wildtype Colorectal Cancer
Interventions: Drug: Erythromycin;   Drug: Doxycycline
11 Recruiting COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Other: Blood analysis by EPISPOT and Cellsearch
12 Active, not recruiting Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Biological: Cetuximab;   Biological: RAD001
13 Recruiting Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal
Condition: Carcinoma of Anal Canal
Interventions: Radiation: RADIOTHERAPY;   Biological: PANITUMUMAB;   Drug: MITOMYCIN;   Drug: CAPECITABINE
14 Completed Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
Condition: Upper Gingival Squamous Cell Carcinoma
Intervention: Other: Blood sample for identifying the polymorphism
15 Recruiting Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Conditions: Colorectal Cancer Metastatic;   C-met Overexpression
Intervention: Drug: Tivantinib (ARQ197)
16 Recruiting Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
Conditions: Head and Neck Neoplasms;   Laryngeal Neoplasms;   Mouth Neoplasms;   Pharyngeal Neoplasms
Interventions: Drug: cetuximab (associated with radiotherapy);   Drug: cisplatin (associated to radiotherapy)
17 Recruiting Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Capecitabine Plus Mitomycin
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: oxaliplatin;   Drug: raltitrexed;   Drug: mitomycin C;   Drug: capecitabine
18 Completed Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Biological: Sym004
19 Completed Anti-EGFR Immunoliposomes in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: anti-EGFR immunoliposomes loaded with doxorubicin
20 Suspended A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
Condition: Gliomas
Intervention: Drug: MAb-425

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years